Key Takeaways
- B&C overtakes Oral Care, validating the strategy: In September, Beauty & Cosmetics revenue exceeded Oral Care for the first time, becoming the largest category, a milestone that proves the diversification bet is paying off.
- Pricing muscle fully recovers cost inflation: The company proactively led price discussions and recovered the entire raw material inflation during the quarter, keeping underlying EBITDA margins above the 20% target.
- Europe operational snag is a 2–3 quarter drag: Regulatory delays in Poland forced higher outsourcing costs, and stabilization will take another 2–3 quarters, a self-inflicted but temporary margin headwind.
- Merger with Indovida is on track, but details are scarce: NCLT application is filed and management is confident on timeline, yet it declined to share Indovida’s current performance or any merged-entity guidance, leaving investors to wait.
- What to watch next quarter: Whether the Poland operations begin to stabilize on schedule, the pace of B&C’s continued share gains now that it is the largest segment, and any concrete synergy numbers once the Indovida merger closes.
B&C Milestone & Growth Drivers
- Category leadership flipped: B&C revenue surpassed Oral Care in September, making it the largest category, a direct result of sustained investment in capabilities and capacity built ahead of demand.
- Growth engine is broad-based: B&C grew 43% (or 40% per a later reference), driven by 130 bps of global market share gains, entry into the extruded segment in white-space markets like China, and premiumization-led market growth in high-share markets like India.
- Front-end specialization unlocked growth: Sales teams for oral and B&C have been separated in most markets, replacing a model where the same person sold both, which management credits for sharper execution.
- No cannibalization fear: With both categories now roughly equal at ~44% of revenue each, management is focused on doing what is right for each independently, dismissing concerns that one category’s growth comes at the other’s expense.
Bakshi: "In the month of September, B&C revenues exceeded that of Oral Care, becoming our largest category. This is a significant milestone and clear demonstration that our strategy is delivering in full and investments being made in this segment are translating into growth and market share gains."
Margin Structure & Cost Recovery
- Underlying margins are healthy, reported optics are not: Reported gross margin of 56.7% and EBITDA margin of 18.9% are depressed by the mathematics of cost-plus pricing, where both numerator and denominator inflate. Underlying gross contribution is 60.5% and underlying EBITDA margin is 20.4%, within the 20%+ target.
- Full inflation recovery achieved: The entire raw material cost increase was recovered through pricing during the quarter, a contrast to prior commodity cycles where the company lagged.
- Operating leverage was reinvested: Despite strong top-line growth, EBITDA margin did not expand further because management chose to invest in a B&C innovation center, outsourced capabilities like metallization, and superior customer service including air freight and higher inventory for on-time delivery.
- Europe drag is temporary but real: Centralizing operations into a Poland printing site hit regulatory delays of 6–9 months longer than anticipated, forcing higher outsourcing costs. Approvals are now in hand and the transition is underway, but full stabilization and margin recovery will take another 2–3 quarters.
Goyal: "Our gross margin is very strong right now. If you look at our gross margin, the gross contribution in this quarter as reported is 56.7, but that looks depressed purely from optical reasons, because mathematically, as the cost goes up and we recover that through price in the math of it, both the numerator, denominator go up and the percentage looks depressed."
Pricing & Competitive Positioning
- A new pricing muscle has been built: Management states it has learned from past commodity crises and now proactively leads price discussions with customers, recovering costs in full and keeping margins stable, a structural improvement in commercial capability.
- Service-as-a-moat strategy: The company air-freighted tubes to meet customer timelines during the crisis, absorbing the cost to deliver superior service, a move management says was rewarded with market share gains across almost all markets.
- Market share gains are material: The company gained 130 bps of global market share over the last year, attributed directly to uninterrupted superior service during the inflationary period.
- Sustainable tubes are a conversion play, not a margin play: The company prices sustainable tubes close to non-sustainable ones to drive adoption, recovering the slightly higher cost but not extracting additional margin, prioritizing volume shift over near-term profit.
Bakshi: "We've learned our lessons, built a pricing muscle. Our sales teams are being very active in the market, and we are proactively leading the price discussion with our customers."
Indovida Merger: Progress & Unanswered Questions
- Approvals are advancing: Competition Commission of India, foreign antitrust authorities, and stock exchanges have all approved the merger. The application is now filed with the NCLT and the process is advancing as planned, with completion expected by Q4 FY27.
- Synergy range is retained but not detailed: Management reiterated the USD 35–50 million synergy range, to be realized over three years post-merger, with a larger proportion on the top line. Geographical expansion is a significant synergy area, as Indovida is strong in Southeast Asia and Africa, markets EPL is keen to enter.
- Management declined to share Indovida’s current performance: When asked about Indovida’s H1 growth and margin impact, management stated the businesses still operate independently and it is not in a position to share unpublished data, with Indovida’s results due on November 9.
- No merged-entity guidance yet: Management explicitly declined to provide guidance for the combined company, stating it will only be done after merger completion and post-merger integration work, and provided no numerical sales synergy estimate despite analyst questions.
- Post-merger balance sheet optionality: With a strong balance sheet at debt-to-EBITDA of roughly 0.2–0.25x, the company will have capacity for acquisitions aimed at geographical expansion or differentiated capabilities after the merger closes.
Regional & Category Performance
| Market / Category | Trend | Commentary |
|---|---|---|
| EAP | ▲ 40% growth | Strongest regional performer. |
| Europe | ▲ 30.4% growth | Top-line strong but operational challenges in Poland are a margin drag for 2–3 more quarters. |
| AMESA | ▲ 28% growth | Broad-based strength. |
| Americas | ▲ 25% growth | U.S. is a significant B&C market where the company is investing to build a larger presence. |
| India (standalone) | ▲ 30% growth | Driven by market growth and share gains from existing customers; premiumization is driving consumption. |
| B&C | ▲ 42.9% growth | Now the largest category; growth from share gains, white-space entry, and market growth. |
| Oral Care | ▲ 19.2% growth | Solid growth despite B&C overtaking it in absolute revenue. |
| Brazil | ▲ Strong | Built over several years by bringing superior quality to the market; cited as a model for new market entry. |
| Thailand | ▲ Progressing | Last greenfield plant; entered via Indorama relationship; strong customer pipeline; model to be replicated post-merger. |
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | High-teens, expected at the higher end closer to 20% | Next few quarters |
| Underlying EBITDA margin | 20% plus | Sustained |
| Europe margin recovery | Operations fully stabilized, margins back to desired levels | 2–3 quarters |
| Full-year capex | ₹625 crore to ₹700 crore, all growth-oriented | FY27 |
| Merger completion | NCLT approval and closing | Q4 FY27 (Q4 consolidation possible but not certain) |
| Merger synergies | USD 35–50 million, realized over 3 years post-merger | 3 years post-merger |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue growth | 30% YoY, highest ever growth declared by the company |
| Underlying revenue growth | 20.3% YoY, excluding pass-through impact of higher raw material prices |
| EBITDA growth | 17.6% YoY, 16th consecutive quarter of double-digit EBITDA growth |
| Reported EBITDA margin | 18.9% |
| Underlying EBITDA margin | 20.4%, excluding inflation-led pricing in denominator |
| PAT growth | 5.6% YoY, impacted by higher depreciation, higher effective tax rate due to country mix, and adverse forex movements |
| Gross margin (reported) | 56.7% |
| Gross margin (underlying) | 60.5%, excluding inflationary cost |
| H1 FY27 capex | ₹315 crore, almost 90% increase over same period last year |
| Full-year capex guidance | ₹625 crore to ₹700 crore |
| Beauty & Cosmetics revenue growth | 42.9% YoY; became largest category in September, overtaking Oral Care |
| Oral Care revenue growth | 19.2% YoY |
| Europe revenue growth | 30.4% YoY |
| EAP region revenue growth | 40% YoY |
| AMESA region revenue growth | 28% YoY |
| Americas region revenue growth | 25% YoY |
| India stand-alone revenue growth | 30% YoY |
| Global market share gain | 130 basis points in last 1 year, per management estimate |
| Sustainable tubes share | 41% of product mix |
| Normal capacity utilization | 60% to 65% on rated capacity |
| Indovida merger synergy target | $35 million to $50 million over 3 years post-merger |
| Post-merger expected debt-to-EBITDA ratio | 0.2x to 0.25x |
| Post-merger share count | 51 crore shares |
| Combined PAT (EPL + Indovida) | ~₹800 crore+ (per an analyst's math) |
| FY27 revenue estimate | ~₹5,900 crore (±1–2%), implied by high-teens/20% growth guidance for H2 (per an analyst's math) |